IMPACT Therapeutics Sets Date and Shareholder Rules for 2026 Extraordinary Meeting

IMPACT Therapeutics, Inc. Class H ( (HK:7630) ) just unveiled an announcement.IMPACT Therapeutics, Inc. has announced plans to convene its first extraordinary general meeting of 2026 on July 27 in Hong Kong, with the shareholder register to be closed from July 22 to July 27 to determine eligibility to attend and vote. Share transfers must be lodged by July 21, and the company will later dispatch and publish detailed meeting documents, underscoring standard governance procedures and clarifying participation rules for its H-share investors.The announcement also confirms the current composition of IMPACT Therapeutics’ board, listing executive, non-executive and independent non-executive directors, which highlights the company’s established governance structure ahead of the meeting. By setting out the timetable and mechanisms for shareholder involvement, the company provides clarity to investors and signals its adherence to Hong Kong listing rules and corporate transparency practices. The most recent analyst rating on (HK:7630) stock is a Hold with a HK$37.60 price target. To see the full list of analyst forecasts on IMPACT Therapeutics, Inc. Class H stock, see the HK:7630 Stock Forecast page. More about IMPACT Therapeutics, Inc. Class H IMPACT Therapeutics, Inc. is a joint stock company established in the People’s Republic of China with limited liability, listed in Hong Kong under stock code 7630. The company operates in the biopharmaceutical and therapeutics sector, focusing on innovative medical treatments and serving global investors through its H-share listing on the Stock Exchange of Hong Kong Limited. Average Trading Volume: 992,279 Current Market Cap: HK$5.79B